The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of March 20, 2025
Completed
Keywords
ClinConnect Summary
Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection.
Patients are randomized to receive either standardized point acupuncture or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks. Acupuncture points...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • Antiretroviral therapy.
- • Nonsystemic treatment of Kaposi's sarcoma.
- • Maintenance with an existing regimen of analgesic medication or herbal treatment.
- Concurrent Treatment: Required:
- • Acupuncture.
- Patients must have:
- • HIV infection.
- • Lower extremity peripheral neuropathy secondary to HIV infection.
- • Pain for at least 2 weeks prior to study entry.
- • Life expectancy of at least 6 months.
- NOTE:
- • Co-enrollment in other experimental protocols is permitted as long as dual participation is allowed in those protocols.
- Prior Medication:
- Allowed:
- • Antiretroviral therapy.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • Known allergy to amitriptyline (not applicable for patients at sites using an acupuncture only study design).
- • EKG indicating malignant arrhythmia or cardiac conduction disturbances (not applicable for patients at sites using an acupuncture only study design).
- • Prison incarceration.
- Concurrent Medication:
- Excluded:
- • Active treatment for an acute opportunistic infection or malignancy (nonsystemic treatment of Kaposi's sarcoma is permitted).
- • Other tricyclic antidepressants.
- • MAO inhibitors.
- Patients with the following prior conditions are excluded (not applicable for patients at sites using an acupuncture only study design):
- • History of cardiac disease.
- • History of seizure disorder.
- Prior Medication:
- Excluded within 2 weeks prior to study entry:
- • MAO inhibitors.
- • Tricyclic antidepressants.
Trial Officials
Shlay J
Study Chair
Flaws B
Study Chair
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Washington, District Of Columbia, United States
Detroit, Michigan, United States
Newark, New Jersey, United States
New York, New York, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
San Francisco, California, United States
Portland, Oregon, United States
Baltimore, Maryland, United States
Albuquerque, New Mexico, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials